Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
406.66 K
Value Traded
-
Short % Float
9.7%
Days to Cover
4.3
+2.01%Week
-0.75%1 Month
+2.17%3 Month
+2.17%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
666.02 M
EPS (TTM)
-0.36
P/E Ratio
-
Ent. Value
707.34 M
Total Shares
101.92 M
Float Shares
70.04 M
Insiders
29.95%
Institutions
37.15%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
STLN Catalyst Timeline
Dated clinical, regulatory and corporate events for Starling Oncology, Inc.
Past FDA Catalysts and PDUFA Decisions
How STLN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every STLN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hively BradDirector | Sell | -298,853 411,976 held | $6.51 | 08/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in STLN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in STLN for Q2 2026. | ||||
STLN Institutional Ownership Trends
STLN Short Interest
Shares sold short, counted twice a month.
9.7%
Short % of Float
of tradable shares sold short
6.8M
Shares Sold Short
-3.7% vs prior count
4.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.6M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How STLN ranks across every disease it competes in
Competitive Position is a premium feature
See how STLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSTLN News
-STLN
Oct 26, 2026▼ -2.7%today
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
Starling Oncology, Inc. will release its third quarter 2026 financial results on November 5, 2026. A conference call will follow at 5:00 p.m. ET, accessible via phone or webcast. The company is known for its value-based cancer care and operates over 100 clinics across five states.
Read more →-STLN
Oct 1, 2026Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
Starling Oncology highlighted its leadership team's participation in recent and upcoming industry conferences, showcasing its commitment to advancing value-based community oncology. Key presentations included discussions on novel therapies, clinical trial access, and integrating behavioral health into cancer care. The company aims to align clinical innovation with improved patient outcomes through its community-based care model.
Read more →-STLN
Aug 24, 2026▼ -5.2%on this news
Starling Oncology to Participate in Wells Fargo Healthcare Conference
Starling Oncology, Inc. will participate in the Wells Fargo Healthcare Conference on September 8, 2026. CEO Dr. Daniel Virnich and CFO Rob Carter will engage in a fireside chat during the event. The presentation will be accessible via a webcast on the company's Investor Relations website.
Read more →-STLN
Aug 17, 2026Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale
Starling Oncology has launched Starling Nexus, a technology platform aimed at optimizing oncology provider engagement and improving compliance with NCCN guidelines. This platform integrates clinical decision support with utilization management to streamline the prior authorization process, thereby enhancing care delivery for patients. Starling Nexus is designed to reduce administrative burdens and improve the overall efficiency of cancer care.
Read more →-STLN
Aug 6, 2026▲ +28.5%on this news
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
Starling Oncology, Inc. reported a strong second quarter for 2026, with revenue rising 34.6% to $161.3 million and a positive Adjusted EBITDA of $229,000. The company has raised its full-year revenue guidance to between $650 million and $670 million, reflecting robust operational growth and new partnerships. However, it still reported a net loss of $9.8 million, albeit an improvement from the previous year.
Read more →-STLN
Aug 3, 2026The Oncology Institute Rebrands as Starling Oncology
The Oncology Institute has rebranded to Starling Oncology, effective August 4, 2026. The new ticker symbol STLN will replace TOI on Nasdaq. CEO Dan Virnich highlighted the company's commitment to accessible, high-quality cancer care and its evolution into an integrated oncology platform. Patients and providers will experience no disruption during this transition.
Read more →-STLN
Jul 27, 2026The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call
The Oncology Institute, Inc. will release its second quarter 2026 financial results on August 6, 2026. A conference call will follow the release at 5:00 p.m. Eastern Time. Investors can access the call via phone or a webcast on the company's Investor Relations website.
Read more →-STLN
Jul 7, 2026The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
The Oncology Institute repaid its $86 million convertible note with Deerfield Partners through a refinancing deal with OrbiMed. This includes a new $75 million term loan and approximately $11 million in cash. The transaction aims to enhance liquidity and extend debt maturities while avoiding shareholder dilution. TOI's CEO expressed excitement about the partnership with OrbiMed.
Read more →-STLN
May 26, 2026The Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring Conference
The Oncology Institute's Chief Medical Officer, Dr. Yale D. Podnos, will speak at the APG Spring Conference on May 28, 2026. He will discuss the importance of specialists in value-based care and how these models can enhance patient outcomes and reduce costs. The Oncology Institute is recognized for its specialized, value-based cancer care across multiple states.
Read more →-STLN
May 13, 2026The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference
The Oncology Institute announced its participation in the B. Riley Securities Institutional Investor Conference on May 21, 2026. CEO Dr. Daniel Virnich and CFO Rob Carter will engage in a fireside chat during the event. A webcast of the presentation will be available on the company's Investor Relations website.
Read more →About Starling Oncology, Inc.
Headquarters18000 STUDEBAKER RD, CERRITOS, CA, 90703
BIOPHARMAWATCH ELITE PLUS
Trade the next STLN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime